5 studies on Ghrh receptor agonist mechanism curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
**GHRP-2's secretagog efficacy is uniquely insensitive to the hormonal and metabolic factors that blunt GHRH-driven GH release**, including visceral adiposity and the IGF-1 / IGFBP axis. For clinicians and researchers…
**Weekly or biweekly dosing** replacing daily GHRH injections is a substantial practical advance for any GH-optimization protocol. Clinicians and researchers investigating GH axis restoration — whether for **GH defici…
**Dosing frequency is the decisive variable** for CJC-1295 efficacy — every-24-hour administration is the threshold at which full growth rescue occurs in this model, while every-48-hour dosing yields only partial bene…
**Continuous GHRH stimulation does not blunt GH pulsatility** — a concern that had been a theoretical barrier to long-acting GHRH therapeutics. For clinicians and researchers, this validates the mechanistic rationale …
**Identifying reliable serum biomarkers of GH action is a critical unmet need** both for anti-doping enforcement and for titrating GH replacement therapy in clinical practice. The linear IGF-1 correlation with the imm…